Capital Markets

Abacus Health Products in its going public transaction by way of a reverse takeover, US$15 million concurrent financing and listing on the Canadian Securities Exchange

Abacus Health Products, Inc.
Expertise
Capital Markets
Key Contact
Eric M. Levy

Partner, Corporate, Toronto

Team
Jason Comerford

Partner, Corporate, New York

Bastien Gauthier

Partner, Corporate, Montréal

Manon Thivierge

Partner, Tax, Montréal

Jean-Philippe Bertrand

Associate, Corporate, Montréal

On January 29, 2019, Abacus Health Products, Inc. (“Abacus”), a Delaware corporation, completed its previously announced going public transaction by way of a reverse takeover of an Ontario corporation formerly known as World Wide Inc. and renamed Abacus Health Products, Inc. In connection with the transaction, Abacus completed a private placement for gross proceeds of US$15 million. The subordinate voting shares of the resulting issuer became listed on the Canadian Securities Exchange following the closing of the transaction.

Abacus is a company engaged in the development and commercialization of over-the-counter (OTC) topical pain-relieving medications registered with the U.S. Food and Drug Administration which contain CBD, a cannabinoid-rich hemp extract.

Osler, Hoskin & Harcourt LLP represented Abacus with a team consisting of Eric Levy, Jason Comerford, Bastien Gauthier, Jie Chai, Jean-Philippe Bertrand (Corporate), Manon Thivierge and Kevin Colan (Tax).

 

Value
US$15 million
Date Closed
January 29, 2019
Lead Office
Montréal
Key Contact
Eric M. Levy

Partner, Corporate, Toronto

Team
Jason Comerford

Partner, Corporate, New York

Bastien Gauthier

Partner, Corporate, Montréal

Manon Thivierge

Partner, Tax, Montréal

Jean-Philippe Bertrand

Associate, Corporate, Montréal